ResMed Inc. (RMD)
Valuation Overview•Is ResMed Inc. Overvalued or Undervalued?
Trading at a discount across both intrinsic cash flow and relative peer multiples, indicating a strong margin of safety.
High-quality fundamentals with a strong composite quality score of 95/100, backed by robust profitability and solvency.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Elite compounder with fortress-level fundamentals across every core pillar.
Wall Street is highly bullish, projecting significant upside with steady expected earnings growth. This is paired with healthy capital returns, anchored by a strong, well-covered dividend yield.
RMD exhibits elite business quality, driven by exceptional capital efficiency and highly lucrative margins (highlighted by a massive 22.8% ROIC). This is backed by a fortress balance sheet, holding significant net cash ($358M) and minimal debt risk.
The company demonstrates solid revenue growth (12.9% 3Y CAGR) paired with highly explosive earnings growth (21.5% EPS 3Y CAGR). This growth is supported by elite operational efficiency, sustaining an impressive 34.3% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | +9.8% | +12.9% | +11.7% | +11.9% | |
| EBITDA | $499.8M | — | +17.2% | — | — | |
| Net Income | $398.7M | +37.2% | +21.6% | — | +14.8% | |
| EPS (Diluted) | $2.71 | +37.4% | +21.5% | +17.4% | +14.4% | |
| Free Cash Flow | $520.5M | +29.2% | +104.2% | +19.0% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 61.7% | 57.3% | 57.2% | 57.7% |
| Operating Margin | 34.3% | 29.2% | 28.8% | 26.1% |
| Net Margin | 27.4% | 23.4% | 21.4% | 19.3% |
| FCF Margin | 31.7% | 24.3% | 19.6% | 19.7% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $2.80 | $2.86 | +2.1% | ||
| Q1'26 | $2.74 | $2.81 | +2.6% | ||
| Q4'25 | $2.51 | $2.55 | +1.6% | ||
| Q3'25 | $2.55 | $2.55 | +0.0% | ||
| Q2'25 | $2.38 | $2.37 | -0.4% | ||
| Q1'25 | $2.32 | $2.43 | +4.7% | ||
| Q4'24 | $2.04 | $2.20 | +7.8% | ||
| Q3'24 | $2.07 | $2.08 | +0.5% |
Total return is -23.9% (1Y), lagging the benchmark by -48.8%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -22.5% | -31.8% | — |
| 1Y | -23.9% | -48.8% | +1.0% |
| 3YCAGR | -3.5% | -23.4% | +3.0% |
| 5YCAGR | -3.5% | -16.5% | +4.2% |
| 10YCAGR | +13.1% | -0.3% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about ResMed Inc. (RMD) valuation, health, and returns.
ResMed Inc. is estimated to be undervalued under our discounted cash flow framework. relative multiples indicate the stock is Cheap versus peers compared to industry peers. undervalued (implying +39.0% upside to DCF intrinsic value of $262.14)
ResMed Inc. has multiple valuation anchors: DCF Intrinsic Value: $262.14 | Peer Relative Fair Value: $253.63 | Wall Street Analyst Target: $264.86 (implying +40.4% upside). A convergence of these signals offers higher conviction.
ResMed Inc. displays excellent financial health with a composite quality score of 95/100, supported by a Altman Z-Score of 10.1 (safe zone), Piotroski F-Score of 8/9, Return on Invested Capital (ROIC) of 22.8%.
ResMed Inc. pays a 1.1% dividend yield, covered by a 22% payout ratio with 14 years of growth, supplemented by a 1.1% buyback yield.
ResMed Inc.'s current growth trajectory is Decelerating. The company achieved +9.8% 1Y revenue growth and +37.4% 1Y EPS growth, compared to its 3Y revenue CAGR of +12.9%.
Wall Street consensus is Buy based on 35 analysts, beating EPS expectations in 75% of recent quarters with a 3-quarter streak. The consensus price target represents a +40.4% change from current levels.
Investment risks for ResMed Inc. include: -37.8% 1-year max drawdown. Volatility risk is characterized by a beta of 0.55x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.